Company profile

Chongqing Precision Biotech Co., Ltd

Privately held: no public share price (AML registry sponsor; ownership/ticker not yet curated.)

Assets

(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
2Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
BCMA-targeted Prime CAR-T cells (Chongqing Precision Biotech)
Phase 2
BCMACell therapy
Multiple Myeloma
CD123 targeted CAR-NK cells
Phase 2
CD123
Acute Myeloid Leukemia
Anti-CD123 CAR NK cells
Phase 1
CD123
Acute Myeloid Leukemia
C-4-29
Phase 1
BCMA; CD70Cell therapy
Multiple Myeloma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.